Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer

NCT02845856 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Non-small Cell Lung Cancer

Interventions

DRUG: Cetuximab
BIOLOGICAL: NK immunotherapy

Sponsor

Fuda Cancer Hospital, Guangzhou

Collaborators

[object Object]